Results 81 to 90 of about 7,132,139 (192)

Therapeutic and Prophylactic Agents for Viral Diseases: Current Status, Challenges, and Future Prospects

open access: yesMedComm, Volume 7, Issue 11, November 2026.
This review summarizes current therapeutic and prophylactic strategies for global viral diseases, including vaccines, PrEP, direct‐acting antivirals, and emerging modalities such as CRISPR and siRNA. It highlights their clinical impact, ongoing challenges, and future priorities toward broader protection, improved delivery, and more effective antiviral ...
Sawar Khan   +12 more
wiley   +1 more source

Metronidazole Attenuates the Intensity of Inflammation in Experimental Autoimmune Uveitis

open access: yesFolia Biologica, 2019
Autoimmune uveitis is a serious sightthreatening disease that in many cases fails to respond to conventional immunosuppressive or biological therapy. Experimental models used in research allow more detailed study of pathogenesis of the autoimmune process and testing new therapeutic strategies.
P, Seidler Stangova   +5 more
openaire   +2 more sources

Comparative Efficacy and Safety of Systemic Immunomodulatory Therapies for Non‐Infectious Uveitis: A Systematic Review With Pairwise and Network Meta‐Analyses

open access: yesPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 11, November 2026.
ABSTRACT Introduction Non‐infectious uveitis (NIU) is a chronic immune‐mediated ocular inflammatory disease that may cause irreversible visual impairment. The comparative efficacy and safety of systemic immunomodulatory therapies, including conventional agents and biologics, remain incompletely defined.
Kai‐Yang Chen   +2 more
wiley   +1 more source

Table1_TNF-α in Uveitis: From Bench to Clinic.DOCX

open access: yes, 2021
Uveitis is an inflammation of the iris, ciliary body, vitreous, retina, or choroid, which has been shown to be the first manifestation of numerous systemic diseases.
Runping Duan (11271141)   +5 more
core   +1 more source

Headache disorders among Indigenous communities: A scoping review undertaken with knowledge keeper guidance

open access: yesHeadache: The Journal of Head and Face Pain, Volume 66, Issue 10, Page 2472-2488, November/December 2026.
Abstract Objective We performed a scoping review of literature on headache etiology, classification, prevalence, and treatment in Indigenous communities in Canada, the United States, Australia, and New Zealand. Background In the United States, analysis of national prevalence indicates that Indigenous Americans lead all other racial/ethnic groups in ...
Maia Kelly   +6 more
wiley   +1 more source

An Aggregation‐Induced Polymerization Poly(Disulfide)‐Drug Nanoplatform for Autoimmune Uveitis Therapy via Inhibiting the cGAS‐STING Pathway

open access: yesAdvanced Science, Volume 13, Issue 59, 23 October 2026.
A cationic poly(disulfide)‐drug nanoplatform (LA/DexP) was developed to treat experimental autoimmune uveitis (EAU). With potent blood‐retinal barrier penetrability, LA/DexP releases DSP in response to high ROS and scavenges cfDNA to inhibit the cGAS‐STING signaling pathway.
Yuelan Wu   +12 more
wiley   +1 more source

CTLA-4 expression on tregs is needed for suppression of autoimmune uveitis

open access: yesScientific Reports
Uveitis is a leading cause of blindness in the world and autoimmune uveitis is an ocular tissue specific autoimmune disease. Utilizing experimental autoimmune uveitis (EAU), we can interrogate different immune responses in the mouse that are relevant to ...
Minjun Ahn   +3 more
doaj   +1 more source

Antigen-Specific Suppressor Cells in Experimental Autoimmune Uveitis

open access: yesOphthalmic Research, 2009
Anti-I-A antibodies, administered in vivo at the time of S-antigen injection, suppress development of experimental autoimmune uveitis (EAU) in Lewis rats. While the effects of anti-I-A are profound, the exact mechanism for this suppression is unknown.
N A, Rao   +5 more
openaire   +2 more sources

CRALBP is a Highly Prevalent Autoantigen for Human Autoimmune Uveitis [PDF]

open access: yes, 2007
Cellular retinaldehyde binding protein (CRALBP) is an autoantigen in spontaneous equine recurrent uveitis. In order to test whether CRALBP contributes to human autoimmune uveitis, the specificity of antibodies from human uveitis patient's sera was first ...
Stephan R. Thurau   +26 more
core   +1 more source

Soluble CD83 Alleviates Experimental Autoimmune Uveitis by Inhibiting Filamentous Actin-Dependent Calcium Release in Dendritic Cells

open access: yesFrontiers in Immunology, 2018
Soluble CD83 (sCD83) is the extracellular domain of the membrane-bound CD83 molecule, and known for its immunoregulatory functions. Whether and how sCD83 participates in the pathogenesis of uveitis, a serious inflammatory disease of the eye that can ...
Wei Lin   +12 more
doaj   +1 more source

Home - About - Disclaimer - Privacy